logo
Plus   Neg
Share
Email

Santarus NDA For Inflammatory Bowel Disease Therapy Uceris Accepted By FDA

Santarus Inc. (SNTS) Wednesday reported that the United States Food and Drug Administration, or FDA, accepted for filing its New Drug Application, or NDA, seeking approval to market Uceris tablets as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review by mid-October 2012.

The NDA seeks to market Uceris in a 9 milligram, or mg, tablet. Also, Cosmo Pharmaceuticals SpA-owned Cosmo Technologies Ltd., a collaborator in the development of Uceris, is now eligible to $4 million in cash or stock as a milestone payment, Santarus Said.

A form of inflammatory bowel disease, or IBD, ulcerative colitis can cause inflammations and ulcers along the colon, resulting in such effects as diarrhea, frequent bowel movements and bleeding. About 1.4 million Americans suffer from IBDs. Uceris is the trade name for budesonide, which is a corticosteroid with topical anti-inflammatory properties.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Russia's biggest two banks, Sberbank and Alfa Bank, are planning to test several private banking products based on cryptocurrencies in a regulatory sandbox environment hosted by the Russian central bank, the Kommersant newspaper reported. After coming under pressure early in the session, stocks regained some ground over the course of the trading day on Friday. The major averages climbed well off their lows of the session, with the S&P 500 briefly turning positive. President Donald Trump's former campaign chairman Paul Manafort is headed to jail after his bail was revoked by a District Court Judge on Friday. Manafort will remain in jail as he awaits trial on criminal charges related to his lobbying work for a pro-Russia party in Ukraine.
Follow RTT